AUREON UNVEILS PROSTATE CANCER TEST
-
- May
- 19
Aureon Laboratories Inc. of Yonkers said it has introduced Prostate Px®+, a commercial test to predict prostate cancer progression and disease recurrence.
The test will forecast disease progression after treatment, and will detect high-risk patients that appear as low risk and undetectable by other methods, said Dr. Ricardo Mesa-Tejada, vice president of pathology and medical director of Aureon. The test also can reclassify intermediate-risk patients, and help identify those with less aggressive forms of the disease, he said.
The announcement was made at the American Urological Association annual meeting at the Orange County Convention Center in Orlando, Fla.
This entry was posted
on Monday, May 19th, 2008 at 2:47 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical, Health care, New products
Print
| 
Email
